What is Cytox?
Cytox Limited specialized in transforming healthcare by providing genetic risk assessment for late-onset Alzheimer's disease. Their core offering involved polygenic risk scoring, a methodology designed to help pharmaceutical and biotech companies more efficiently identify and stratify patient candidates for clinical trials. The company's services extended to assessing amyloid status, cognitive decline, and profiling mTOR-associated pathways, aiming to enable precise drug targeting. Despite its innovative approach to disease risk stratification, Cytox was unfortunately placed into liquidation in January 2024.
How much funding has Cytox raised?
Cytox has raised a total of $11.1M across 3 funding rounds:
Series A
$5.3M
Series B
$2.5M
Unspecified
$3.3M
Series A (2013): $5.3M, investors not publicly disclosed
Series B (2014): $2.5M led by Seneca Partners Ltd., Spark Capital, Wren Capital, and Northwest Fund
Unspecified (2017): $3.3M supported by The Rainbow Seed Fund, Perivoli Innovations, Catapult Ventures, GM&C Life Sciences Fund, and The University of Oxford
Key Investors in Cytox
The Rainbow Seed Fund
The Rainbow Seed Fund, part of UKI2S, is a significant pre-seed+ fund in the UK, managing £110 million. It focuses on early-stage businesses tackling global challenges in sectors like defense, engineering biology, fusion, and space, adopting an impact-first approach with mentorship and fundraising support.
Perivoli Innovations
Perivoli Innovations, established in 2016, is a venture investment trust focused on early-stage investments in medical, life science, climate science, digital, and productivity-enhancing technologies, with a commitment to donating profits to the Perivoli Foundation for initiatives in Africa.
Catapult Ventures
Catapult Ventures provides tailored investment solutions for entrepreneurs and business owners, focusing on unlocking potential and supporting clients' goals. They position themselves as a reliable investment partner, fostering growth and value through strategic partnerships.
What's next for Cytox?
Given that Cytox was placed into liquidation in January 2024, the forward-looking narrative shifts from growth and scaling to the implications of its cessation. While the company's total funding of $11.1M indicates substantial prior investment and belief in its technology, the liquidation signifies an inability to achieve sustainable commercial success or overcome operational challenges. The strategic investment of $3.3M prior to this outcome suggests a final attempt to stabilize or pivot the business. The legacy of Cytox's work may lie in the intellectual property developed or the data generated, which could potentially be acquired or utilized by other entities in the genetic risk assessment or Alzheimer's research space.
See full Cytox company page
